Rain (RAIN) falls 4.00% in Light Trading on September 14

Equities Staff  |

Rain Therapeutics Inc (NASDAQ: RAIN) fell to close at $16.32 Tuesday after losing $0.68 (4.00%) on volume of 42,293 shares. The stock ranged from a high of $17.09 to a low of $16.02 while Rain’s market cap now stands at $431,937,295.

About Rain Therapeutics Inc

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Visit Rain Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Rain Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Rain Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law
COVID-19 Surge in Idaho Forcing Statewide Health Care Rationing
JPMorgan Launching Its First Overseas Digital Bank in United Kingdom Next Week
Federal Reserve Reviewing Ethics Policies in Wake of Prolific Trading Disclosed by Two Senior Officials
Chinese Property Developer Evergrande Not 'Too Big to Fail' — Global Times
August Retail Sales Rebound 0.7%, Surprising Economists After July Plunge
UN Report Shows COVID-19 Has Not Slowed Pace of Climate Change



Market Movers

Sponsored Financial Content